Is pain the next big frontier for supplements? The pain OTC drug market is enormous, while for nutraceuticals the category isn’t even listed in reports. But not for long. The biggest players have seen the potential of this vast white space and are starting to make moves. In 2023, we have seen a breakthrough in the segment with multiple launches sending shockwaves across the industry.
The perfect example is Haleon expanding their leading Excedrin and Panadol painkiller brands with food supplement alternatives. At Nicholas Hall 34th European CHC Conference 2024 we discussed how the segment is developing and where are the opportunities in this emerging trend. We also presented case studies for two of PharmaLinea’s products addressing the pain segment. Access the event presentation below, to find out more.
